Austedo vs Gabapentin
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Austedo | US Gabapentin | |
|---|---|---|
| Generic name | deutetrabenazine | gabapentin |
| Drug class | VMAT2 Inhibitor | Anticonvulsant / Nerve Pain Agent |
| Treats | Tardive dyskinesia, Huntington's chorea | Nerve pain, seizures |
| Category | Neurology | Neurology |
| Manufacturer | Teva | Various (generic) |
| Year approved | 2017 | 1993 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $150M | $1M |
| Common side effects | Depression and suicidal thoughts (Huntington's), Drowsiness, Fatigue, Dry mouth | Drowsiness, Dizziness, Swelling, Coordination problems |
Gabapentin
Frequently asked questions
Is Austedo or Gabapentin better?
Neither is universally "better." Austedo (deutetrabenazine) and Gabapentin (gabapentin) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Austedo and Gabapentin?
Austedo is a VMAT2 Inhibitor made by Teva, while Gabapentin is a Anticonvulsant / Nerve Pain Agent made by Various (generic). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Austedo has the larger estimated TV advertising budget of the two.